Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RLMD

RLMD - Relmada Therapeutics Inc Stock Price, Fair Value and News

$3.94-0.16 (-3.90%)
Market Closed

61/100

RLMD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

61/100

RLMD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.66

Target 3M

$4.08

Target 6M

$4.26

RLMD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RLMD Price Action

Last 7 days

3.4%

Last 30 days

-11.5%

Last 90 days

69.8%

Trailing 12 Months

994.4%

RLMD RSI Chart

RLMD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RLMD Valuation

Market Cap

288.9M

Price/Earnings (Trailing)

-5.14

Price/Sales (Trailing)

46.26

Price/Free Cashflow

-7.23

RLMD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.66

Target 3M

$4.08

Target 6M

$4.26

RLMD Fundamentals

RLMD Revenue

Revenue (TTM)

6.2M

RLMD Earnings

Earnings (TTM)

-56.2M

Earnings Growth (Yr)

53.55%

Earnings Growth (Qtr)

-2.28%

RLMD Profitability

Return on Equity

-593.46%

Return on Assets

-377.61%

Free Cashflow Yield

-13.84%

RLMD Investor Care

Shares Dilution (1Y)

143.03%

Diluted EPS (TTM)

-1.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20220006.2M
202000818.3K0
20190000
20180000
2017096.4K00
201466.0K000
20136.5K5.8K5.1K35.6K
2012007.9K7.2K
Get all data in R, Python etc through our Historical Stock Data APIs

About Relmada Therapeutics Inc

RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
 CEO
 WEBSITErelmada.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES14

Relmada Therapeutics Inc Frequently Asked Questions

RLMD is the stock ticker symbol of Relmada Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Relmada Therapeutics Inc is 288.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RLMD's fair value in chart for subscribers.

The fair value guage provides a quick view whether RLMD is over valued or under valued. Whether Relmada Therapeutics Inc is cheap or expensive depends on the assumptions which impact Relmada Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RLMD.

As of Wed Jan 28 2026, RLMD's PE ratio (Price to Earnings) is -5.14 and Price to Sales (PS) ratio is 46.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RLMD PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Relmada Therapeutics Inc has provided -0.034 (multiply by 100 for percentage) rate of return.